41° Cloudy

Site search

Open user controls
- Log In Using Your Account
  Log In
  
  Don't have an account? Sign Up Today

- My Account
- Dashboard
- Profile
- Saved items
- Logout

Home
News
- Local News
- State News
Sports
- Local Sports
- Pro Sports
Lifestyle
- Local Entertainment
Multimedia
Community Choice
Features
Classifieds
- Place Ad
- Legal Notices
Public Notices
Obituaries
E-Edition

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Biogen Idec (NQ:BIIB)

191.41 +2.42 (+1.28%)

Streaming Delayed Price Updated: 2:46 PM EST, Feb 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Biogen Idec

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

NASDAQ:BIIB Long Term Investor Alert: Investigation of Potential Wrongdoing at Biogen Inc. ↗

June 10, 2022

San Diego, CA -- (SBWIRE) -- 06/10/2022 -- Certain directors of Biogen Inc. are under investigation over possible breaches of fiduciary duties.

Via SBWire

Rising Cases Of Mental Health Disorders of Stress, Anxiety & Addiction Fueling Need for Central Nervous System Therapeutics

June 07, 2022

Palm Beach, FL – June 7, 2022 – FinancialNewsMedia.com News Commentary – The global Central Nervous System (CNS) treatments and its market revenues had been steadily growing pre-pandemic and are still...

Via FinancialNewsMedia

Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic Targeting the Treatment of Gait Deficits in Multiple Sclerosis

May 05, 2022

From MedRhythms

Via Business Wire

Biogen Leads From the Top With Disability Inclusion

December 03, 2021

SOURCE: Biogen

Via 3BL Media

Sage Therapeutics and Biogen Initiate Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Zuranolone for the Potential Treatment of Major Depressive Disorder (MDD)

May 02, 2022

From Sage Therapeutics, Inc.

Via Business Wire

Biogen Inc. (NASDAQ:BIIB) Investor Notice: Deadline in Lawsuit on April 8, 2022 ↗

March 28, 2022

San Diego, CA -- (SBWIRE) -- 03/28/2022 -- The Shareholders Foundation announced that a deadline is coming up on April 8, 2022 in the lawsuit filed for certain investors of Biogen Inc. (NASDAQ:BIIB).

Via SBWire

NASDAQ:BIIB Investor Alert: Lawsuit Alleges Misleading Statements by Biogen Inc. ↗

February 23, 2022

San Diego, CA -- (SBWIRE) -- 02/23/2022 -- An investor, who purchased NASDAQ:BIIB shares, filed a lawsuit against Biogen Inc over alleged Securities Laws violations.

Via SBWire

BIIB Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Biogen, Inc. Investors of Class Action and Encourages Investors to Contact the Firm

February 14, 2022

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

From Pause to Pride: A Mother's Journey

December 01, 2021

SOURCE: Biogen

Via 3BL Media

Topics LGBTQ

Introducing Biogen's 2021 Diversity, Equity & Inclusion Report

November 04, 2021

SOURCE: Biogen

Via 3BL Media

Psychedelic Drugs Market Growing as Prevalence of Mental Health Issues are Increasing Globally

February 24, 2022

Palm Beach, FL –– February 24, 2022 – FinancialNewsMedia.com News Commentary – The prevalence of mental health disorders has risen exponentially but the development of novel medications has not kept...

Via FinancialNewsMedia

Biogen Update

February 13, 2022

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Biogen Class Action Reminder

February 12, 2022

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

BIIB Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Biogen, Inc. Investors of Class Action and Encourages Investors to Contact the Firm

February 11, 2022

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

Shareholder Alert: Robbins LLP Reminds Investors Biogen, Inc. (BIIB) is Being Sued for Misleading Shareholders

February 11, 2022

From Robbins LLP

Via Business Wire

Biogen Shareholder Notice

February 10, 2022

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

BIOGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Biogen, Inc. and Encourages Investors to Contact the Firm

February 09, 2022

From Bragar Eagel & Squire, P.C.

Via Business Wire

Biogen Shareholder Alert

February 09, 2022

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

CORRECTING and REPLACING Shareholder Alert: Robbins LLP Informs Investors Biogen, Inc. (BIIB) is Being Sued for Misleading Shareholders

February 09, 2022

From Robbins LLP

Via Business Wire

Shareholder Alert: Robbins LLP Informs Investors Biogen, Inc. (BIIB) is Being Sued for Misleading Shareholders

February 09, 2022

From Robbins LLP

Via Business Wire

Biogen Deadline Alert

February 08, 2022

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Sage Therapeutics and Biogen Announce New Analyses from the LANDSCAPE Clinical Development Program of Zuranolone in MDD Presented at the American College of Neuropsychopharmacology (ACNP) Congress

December 08, 2021

From Sage Therapeutics, Inc.

Via Business Wire

Sage Therapeutics and Biogen Announce Positive, One-Year Zuranolone 50 mg Data in the Ongoing Open-Label SHORELINE Study in Patients with MDD

December 01, 2021

From Sage Therapeutics, Inc.

Via Business Wire

Youth Neurology Program: Building a More Diverse Neurology Workforce

November 30, 2021

SOURCE: Biogen

Via 3BL Media

Wanda Castro-Borrero: Carrying on Legacy of Care

November 23, 2021

SOURCE: Biogen

Via 3BL Media

Topics LGBTQ

Global Cancer Therapy Market Expected to Reach $268 Billion In 2026, With A CAGR Of 9.15%

November 16, 2021

Palm Beach, FL –November 16, 2021 – FinancialNewsMedia.com News Commentary – The COVID-19 pandemic has affected the healthcare systems globally and also has a significant impact on the cancer therapy...

Via FinancialNewsMedia

Biogen Sets Industry Record with Recognition on Dow Jones Sustainability World Index for 9th Consecutive Year

November 15, 2021

SOURCE: Biogen

Via 3BL Media

Topics Climate Change Stocks Supply Chain

CEO Climate Alliance to World Leaders: We Support You in Taking Decisive Climate Steps at COP26

November 11, 2021

SOURCE: Biogen

Via 3BL Media

Topics Emissions

Biogen Launches Supplier Climate Action Program “Energize” With Leading Pharmaceutical Companies

November 04, 2021

SOURCE: Biogen

Via 3BL Media

Topics Climate Change Supply Chain

A Letter From Alphonse Galdes, Ph.D., Head of Pharmaceutical Operations and Technology at Biogen: It's Time for Companies to Act Like the Climate Crisis Is a Health Crisis

November 03, 2021

SOURCE: Biogen

Via 3BL Media

Topics Climate Change Death Emissions

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

Home
News
Sports
Multimedia
Local Events
Classifieds
Obituaries
Weather
Online Features

Services

About Us
Contact Us
Promote Your Event
Subscriber Services
Online Forms
Rack Locations

woonsocketcall.com
Address: 154 Main Street
Woonsocket, RI 02895
Phone: 401-762-3000
Email: notices@woonsocketcall.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Log In Using Your Account

Biogen Idec (NQ:BIIB)

Press Releases about Biogen Idec

Sections

Services